Molecular mechanisms of liver damage during neoadjuvant treatment for hepatic metastases of colorectal cancer.
CONCLUSION: In our study, after the administration of the "bevacizumab plus FOLFOX IV" protocol, a statistically significant increase in AF, Dbilirubin and LDH, as well as a decrease in albumin values, were found. Dominant liver damage was by type of SOS syndrome (66.7%), while steatosis of the liver was recorded in only 3.3% of patients. Gender, age, the presence of metabolic syndrome and the number of chemotherapy cycles did not have any statistic significance on the biochemical parameters and morphological degree of liver damage.
KEY WORDS: Colorectal cancer metastases, Liver surgery, Oncology, Neoadjuvant chemotherapy, Liver damage.
PMID: 32877385 [PubMed - in process]
Source: Annali Italiani di Chirurgia - Category: Surgery Tags: Ann Ital Chir Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Liver | Metabolic Syndrome | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Statistics | Study | Surgery | Toxicology | Urology & Nephrology